Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone for plaque psoriasis and obesity.

The study demonstrated the efficacy of its drugs Taltz and Zepbound in treating psoriasis and obesity.

27.1% of participants receiving Taltz and Zepbound reached complete skin clearance (Psoriasis Area Severity Index (PASI) 100) and at least 10% weight loss, compared to 5.8% of patients treated with Taltz alone, meeting the primary endpoint.

Taltz and Zepbound delivered a 40% relative increase over Taltz monotherapy in the proportion of patients who achieved PASI 100 (40.6% vs.29%).

Side Effects

The most common adverse events were nausea, diarrhea, constipation, injection site reaction, dosing error, vomiting, and dizziness in the Taltz and Zepbound concomitant treatment arm, and injection site reaction, dosing error, and nasopharyngitis in the Taltz monotherapy arm.

Agreement With Australian Company

CSL Limited (OTC:CSLLY) on Wednesday entered into ...